Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review
Pharmaceuticals · 18.08.2025 · 18 (8) · 1217
DOI: 10.3390/ph18081217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 18.08.2025. Verfasst von Rares-Mircea Birlutiu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department 14-Orthopedics, Anaesthesia Intensive Care Unit, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Periprosthetic joint infections (PJIs) remain among the most challenging complications in orthopedic surgery, often requiring prolonged antibiotic therapy and complex surgical interventions. Oritavancin, a long-acting semisynthetic lipoglycopeptide approved for acute bacterial skin and skin structure infections, has emerged as a potential off-label agent in PJI treatment due to its favorable pharmacokinetic properties, potent Gram-positive coverage, and documented antibiofilm activity.
Objectives
This comprehensive review aims to assess the current clinical and preclinical data regarding the potential use of oritavancin in the management of PJIs.
Methods
A comprehensive literature search was conducted in three major databases.
Results
Six studies were included. In vitro data demonstrated strong activity of oritavancin against methicillin-resistant Staphylococcus aureus and S. epidermidis biofilms, particularly in synergy with rifampin. Clinical reports described successful outcomes in both acute and chronic PJI cases, including those with limited surgical options. Weekly or monthly dosing regimens were well-tolerated and effective in suppressive and curative contexts. Adverse events were infrequent but included infusion-related reactions.
Conclusions
Oritavancin represents a promising adjunct or alternative to conventional antimicrobial regimens in PJIs, particularly for outpatient management or in patients with multidrug-resistant Gram-positive infections. Further prospective studies are needed to define its role, optimal dosing, and long-term efficacy in this complex clinical setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department 14-Orthopedics, Anaesthesia Intensive Care Unit, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Foisor Clinical Hospital of Orthopedics, Traumatology, and Osteoarticular TB, 030167 Bucharest, Romania.
- Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania.
- County Clinical Emergency Hospital, 550245 Sibiu, Romania.
ORCID-Profile: Rares-Mircea Birlutiu, Victoria Birlutiu
Zitieren
APA
Birlutiu, R. M., & Birlutiu, V. (2025). Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review. Pharmaceuticals, 18(8), 1217. https://doi.org/10.3390/ph18081217
Vancouver
Birlutiu RM, Birlutiu V. Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review. Pharmaceuticals. 2025;18(8):1217. doi:10.3390/ph18081217
BibTeX
@article{Birlutiu2025,
author = {Birlutiu, Rares-Mircea and Birlutiu, Victoria},
title = {Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1217},
doi = {10.3390/ph18081217}
}
EUVIMED